A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT05536141 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

362

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Solid Tumors

Interventions

DRUG: casdatifan
DRUG: Cabozantinib
DRUG: Zimberelimab
DRUG: Ipilimumab

Sponsor

Arcus Biosciences, Inc.